Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Activity of Two Interleukins Perpetuate Chronic Autoimmune Conditions

By LabMedica International staff writers
Posted on 25 Jan 2017
A mouse model of "dry eye disease" was used to demonstrate the link between interleukins 7 and 15 and the pathogenic memory Th17 cells that mediate the autoimmune disease.

Th17 (T helper 17) cells are principal mediators of many autoimmune conditions. More...
Persistent memory Th17 cells have been revealed as crucial in mediating the chronicity of various autoimmune disorders; however, the underlying mechanisms maintaining memory Th17 cells have remained elusive.

Investigators at Harvard Medical School used a mouse model of an ocular autoimmune disease to further elucidate the mechanism controlling the behavior of Th17 cells,

The investigators reported in the November 26, 2016, online edition of the Journal of Autoimmunity that both IL-7 and IL-15 were critical for maintaining pathogenic memory Th17 cells. Neutralization of these cytokines led to substantial reduction of memory Th17 cells. Both IL-7 and IL-15 provided survival signals by activating STAT5 (Signal transducer and activator of transcription 5), and IL-15 provided additional proliferation signals by activating both STAT5 and Akt (Protein kinase B).

Topical neutralization of IL-7 or IL-15 in the eye effectively reduced memory Th17 cells at the inflammatory site and draining lymphoid tissues, while topical neutralization of IL-17 alone, the major pathogenic cytokine secreted by Th17 cells, did not diminish memory Th17 cells at the draining lymphoid tissues.

The results obtained during this study suggested that treatment to remove pathogenic memory Th17 cells via abolishing environmental IL-7 or IL-15 would be a novel strategy in the treatment of autoimmune diseases.

“We wanted to know the precise factors that maintain memory in Th17 cells so that we can better understand what is causing chronic autoimmune disorders,” said senior author Dr. Reza Dana, professor of ophthalmology at Harvard Medical School. “By selectively targeting the production and expression of IL-7 and IL-15, we may be able to prevent the development of chronic autoimmune disorders.”

“In the case of dry eye disease, many of the treatments are showing limited efficacy in patients that do not have a highly inflamed eye,” said Dr. Dana. “Targeting the chronic, immune nature of autoimmune diseases may be a better strategy for controlling these conditions.”


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.